AddBIO AB

AddBIO was founded in 2008 to develop and commercialize products for local delivery of drugs from orthopedic and dental implants. The products are based on the proprietary technology platform FibMat, enabling local delivery of a number of drugs from the surface of a medical implant.

The first product from the FibMat platform is Zolidd. Zolidd enhances the holding power of bone implants, through local delivery of a bisphosphonate drug. Good preclinical data has been the base for promising clinical results, and more clinical studies are on-going.

The development and verification of the technology is done in close collaboration with academic scientists, industry professionals, consultants, and a dedicated team of employees at AddBIO. Zolidd will be launched through close collaboration with clinicians in the orthopedic and dental fields, as well as with market players in the orthopedic and dental implant industries.

The FibMat technology platform is based on discoverie by Prof. Aspenberg and Prof. Tengvall, initiated by Professor Aspenberg’s acknowledgement of the problem with screw loosening in orthopedic surgery. Both Aspenberg and Tengvall are founding partners of the company, and part of AddBIO’s international network of clinicians and specialists.

AddBIO is a subsidiary to Accelerator Nordic AB (www.acceleratorab.se).

Qualified management & board

−     Andreas Bunge, Chair

- Andreas is CEO of Accelerator Nordic AB.

−     Stephen Lang (UK)

−     Steve has long experience in the orthopedic industry. For many years he was with Smith & Nephew working with product development and later with Business Development and M&A.

−     Peter Lindell (SE)

−     Peter is a successful Swedish entrepreneur with a multitude of successful startups on his track record.

−     Andrew Carter, Ph.D., (US), Advisor

−     Andy has a long experience from orthopedic industry, and has held positions such as CTO in Anika Therapeutics, VP and GM at Spine Wave, Group Director R&D at Smith & Nephew. His experiences span R&D, commercialization, regulatory processes, and manufacturing.

−     Trine Vikinge, Ph.D., CEO

−     Trine has a background in biomaterials research. She has been with AddBIO since the start, and prior to this served at Accelerator Nordic as a project manager and founder of several university spin-outs.

Advisory Board

−     Anders Jönsson, (SE) Orthopedic Surgeon

−     Anders is an experienced orthopedic surgeon, and presently head of orthopedic trauma at Sahlgrenska University Hospital in Sweden. For 7 years Anders served as a Director for Global Medical Science at Stryker Osteosynthesis, heading their activities in e.g. clinical research.

−     Per  Aspenberg, (SE), Orthopedic Surgeon

−     Per is a renowned professor and scientist with a strong reputation. His interest in drug interaction with bone early led him to investigate effects of locally delivered drugs. Per has published more than 200 scientific peer reviewed articles, and is a frequent guest lecturer at international meetings